Latest News for: subcutaneous
Edit
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
Pharmiweb 24 Feb 2026
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab [1] [2] [3] [4] [5] ... Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies.
Edit
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with ...
Nasdaq Globe Newswire 23 Feb 2026
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ... .
Edit
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer (Johnson & Johnson)
Public Technologies 23 Feb 2026
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer ... Subcutaneous amivantamab..
Edit
NICE Recommends TEPKINLY®▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy
Pharmiweb 23 Feb 2026
Edit
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday (Celltrion Inc)
Public Technologies 19 Feb 2026
"This data provides evidence that subcutaneous infliximab can effectively and safely recapture disease control, offering a viable treatment option for both clinicians and patients." ... About the subcutaneous (SC) formulation of CT-P13.
Edit
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications Français
Canada Newswire 17 Feb 2026
The primary endpoints of the trial demonstrated that the subcutaneous (SC) formulation produced noninferior levels of pembrolizumab in the blood compared to the intravenous (IV) formulation based on pharmacokinetic exposure measures (Ctrough.
Edit
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control ...
Business Wire 16 Feb 2026
today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and ...
Edit
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday
Pharmiweb 16 Feb 2026
“This data provides evidence that subcutaneous infliximab can effectively and safely recapture disease control, offering a viable treatment option for both clinicians and patients.” ... About the subcutaneous (SC) formulation of CT-P13.
Edit
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's ...
JCN Newswire 10 Feb 2026
Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector.
Edit
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s ...
Nasdaq Globe Newswire 09 Feb 2026
(Headquarters ... Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector ... .
Edit
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
PR Newswire 09 Feb 2026
The BLA for the subcutaneous formulation was accepted for review by the NMPA in January 2026 ... In the US, Leqembi Iqlik™ is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer's disease.
Edit
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China (Biogen Inc)
Public Technologies 09 Feb 2026
Viehbacher, "Biogen") announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector ... subcutaneous formulation was accepted in China.
Edit
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the ...
Canada Newswire 04 Feb 2026
Health Canada approves PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg.
Edit
Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus (Form 6-K) (AstraZeneca plc)
Public Technologies 03 Feb 2026
Update on Saphnelo subcutaneous administration ... Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus ... Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (Tulip SC).
Edit
The Eagle-Tribune
26 Jan 2026
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for ...
The Eagle-Tribune
26 Jan 2026
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease ... .
- 1
- 2
- Next page »